Question 1

What is semaglutide?

Accepted Answer

Semaglutide is a long-acting copy of a hormone the gut already makes. A 2019 review of its development describes glucagon-like peptide-1, or GLP-1, as an incretin hormone with important effects on glycemic control and body weight regulation. Incretin means a gut hormone released after eating, and glycemic means relating to blood sugar. The problem the chemists had to solve was time, because the natural hormone does not last. That discovery led to efforts to extend its half-life and make it therapeutically effective in people with type 2 diabetes. Reversible binding to albumin was used for the systemic protraction of liraglutide and semaglutide, and protraction just means making the effect last longer. That is why it is given weekly rather than daily. A 2021 review of this class lists semaglutide among the agents injected once weekly, alongside dulaglutide.

Question 2

Are peptides like Ozempic?

Accepted Answer

Yes and no, and the split is the part worth having. A 2024 review in JAMA groups it with liraglutide and tirzepatide as nutrient-stimulated hormone-based medicines that mimic the actions of enteropancreatic hormones that modify central appetite regulation. Enteropancreatic means arising in the gut and the pancreas, so that is a long way of saying it copies a gut hormone. The chemistry sits in the same family as the research compounds covered elsewhere on this site. What is not the same is the record behind it. Rational design led to the development of two long-acting GLP-1 analogs, liraglutide and semaglutide. Concerns about semaglutide were then addressed in the extensive phase 3 registration trials, which is a line nobody can write about most compounds in this class. The word peptide tells a reader what a molecule is made of. It tells them nothing about what is in a given vial.

Question 3

What is Wegovy, and what is it approved for?

Accepted Answer

Wegovy is one of the names semaglutide is sold under, and the approval behind that name is for weight rather than for blood sugar. A 2022 review titled Wegovy (semaglutide): a new weight loss drug for chronic weight management reports that three trial programmes led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. The approved weekly amount for that use is on record as well. A 2025 trial report states that once-weekly subcutaneous semaglutide 2·4 mg is approved for weight management in people with obesity and related complications. A trade name is worth noticing for one reason. It tells a reader the vial was made to a specification filed with a regulator and dispensed by a pharmacy, which is not true of everything sold under the chemical name.

Question 4

Does semaglutide actually work for weight loss?

Accepted Answer

Yes, and the evidence is stronger than for anything else on this site. In STEP 1, 1,961 adults with a body-mass index of 30 or greater, or 27 or greater with a weight-related condition and no diabetes, were randomly assigned to 68 weeks of once-weekly semaglutide at 2.4 mg or to placebo. The mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo. A second trial put the same question to people who also had type 2 diabetes. Among 1,210 participants, the estimated change in mean bodyweight at week 68 was -9·6% with semaglutide 2·4 mg against -3·4% with placebo. Pooled across six randomised trials in 3,962 overweight or obese adults, the mean difference in body weight was -11.80%. Every figure there is a group average, not an outcome any one person had, and each pairs the injection with a supervised diet and activity programme. What each of those trials set out to measure, outcome by outcome across weight, blood sugar, body composition and the heart, is taken separately at the Semaglutide benefits page.

Question 5

How far into human testing has semaglutide gone?

Accepted Answer

Further than almost anything else covered on this site, and across three programmes rather than one. A 2022 review records that the SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide on participants with type 2 diabetes. The STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. The longest published obesity trial ran for two years. In STEP 5, 304 participants were randomly assigned to semaglutide 2.4 mg or placebo, and 92.8% of them completed the trial. A heart-outcomes trial is larger again, with 9,650 participants enrolled between June 2019 and March 2021 at a mean age of 66.1 years. Teenagers have been studied too. A 2022 trial randomised 201 young participants, of whom 180, or 90%, stayed to the end of it. Trials that big, followed that long, are evidence a reader cannot get for most compounds.

Question 6

What did semaglutide do for blood sugar?

Accepted Answer

The diabetes trials measured HbA1c, the share of haemoglobin carrying attached sugar and the standard marker of glucose control. SUSTAIN 1 enrolled treatment-naive adults with type 2 diabetes managed by diet and exercise alone, and 387 of them received at least one dose. At week 30, HbA1c significantly decreased by 1·45% among the participants assigned to the 0·5 mg weekly amount. A 2021 trial report refers to semaglutide 1·0 mg as the dose approved for diabetes treatment, well under what was later approved for weight. A head-to-head trial puts that in context. In 1,879 patients, the estimated mean change in glycated hemoglobin was -1.86 percentage points with semaglutide, against -2.01 to -2.30 points across three amounts of tirzepatide. What one open-label comparison is worth deserves a page of its own.

Question 7

Is there a pill form of semaglutide?

Accepted Answer

Yes, and it is the only compound in this class that has one. A 2021 review notes that a daily oral preparation of semaglutide, which has demonstrated clinical effectiveness close to the once-weekly subcutaneous preparation, was recently approved. A 2021 safety review calls it the only GLP-1RA currently available as both subcutaneous and oral formulation. The tablet results are real and smaller than the headline injection figures. In a 71-week trial, 205 participants were randomly assigned to oral semaglutide at 25 mg daily and 102 to placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group. A weekly injection and a daily tablet are not taken the same way, and what governs how much of a tablet reaches the blood is on the safety page.

Question 8

What is “Ozempic face”?

Accepted Answer

No study among the research behind this page has measured facial appearance in anybody given semaglutide. The phrase describes something people notice in a mirror, and nothing in the clinical record was designed to measure it. What has been measured is where the weight comes from. A 2024 systematic review of six studies in 1,541 overweight or obese adults found significant weight reductions observed primarily due to fat mass loss. Lean mass stayed stable in some of those studies, while notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others. Read that carefully, because it answers a different question. Those scans measure the whole body rather than a face, and facial fat has not been reported on its own in any of them. The mechanism people describe is plausible and unmeasured, which is not the same as demonstrated.

Question 9

What are “Ozempic vulva” and “Ozempic breasts”?

Accepted Answer

These phrases describe soft tissue changing shape somewhere other than the face, and no study among the research behind this page has measured either. No trial of semaglutide covered here has reported an outcome for breast or genital tissue. What the record contains instead is a whole-body number. Across 22 randomised trials in 2,258 participants, GLP-1 receptor agonists significantly reduced total body weight by 3.55 kg and fat mass by 2.95 kg on average. What it does not contain is any statement about where on the body that fat was carried. Those are different questions and only the first has been asked. Tissue that is partly fat will change when total fat falls, which is reasoning rather than evidence, and the two should not be confused.

Question 10

Why are people stopping Ozempic and Wegovy?

Accepted Answer

Side effects and money, according to the published work that has looked at this outside a trial. A 2025 review of real-world use reports high discontinuation rates of GLP-1RAs of 20% to 50% within the first year, alongside the use of much lower doses than those evaluated in clinical trials. The same review names nausea and digestive problems as the main reasons patients stop taking these treatments, and records that many stop within the first year because of side effects or high cost. That pattern showed inside the trials too, at a far smaller scale. In SUSTAIN 1, 13% and 12% of participants on the two semaglutide amounts discontinued treatment against 11% on placebo, and the main reason was gastrointestinal adverse events such as nausea. The gap between those two sets of numbers is the gap between supervised participants and everybody else.

Question 11

What happens when you stop taking semaglutide?

Accepted Answer

No study among the research behind this page has published a withdrawal trial of semaglutide, a striking gap for a compound carrying this much evidence. A 2025 review of real-world use lists studies of the effects of stopping GLP-1RA treatment among the areas where further research is needed. Two pieces of indirect evidence are worth putting beside that gap. A 2024 narrative review in Diabetes Care proposes that retaining lean mass during incretin therapy could blunt body weight and fat regain on cessation of weight loss pharmacotherapy. A 2023 JAMA review notes that after behavioural weight-loss programmes, weight regain occurs in 25% or more of participants at 2-year follow-up. Neither is an answer. The first is a proposal no study among the research behind this page has tested in a trial, and the second describes a different intervention in a different set of participants.

Question 12

What is known as the “poor man’s Ozempic”?

Accepted Answer

No trial among the research behind this page has measured a cheaper substitute against semaglutide, so the phrase resolves to nothing a reader can check. What the record holds instead is the comparisons that were actually run. The first is a head-to-head against tirzepatide. In a 72-week trial, 751 adults with obesity and without type 2 diabetes received the maximum tolerated dose of tirzepatide or of semaglutide once weekly. The least-squares mean percent change in weight at week 72 was -20.2% with tirzepatide and -13.7% with semaglutide. The second adds a molecule rather than replacing semaglutide with one. In a trial of 3,417 participants, cagrilintide combined with semaglutide produced an estimated mean percent change in body weight of -20.4% against -3.0% with placebo. Anything else offered under that phrase has not been measured against it, and an untested substitute is an absence of a result rather than a cheaper one.

Question 13

What is documented about side effects?

Accepted Answer

One paragraph, because this question has a page of its own. A 2024 JAMA review of obesity medicines reports that adverse effects of this class include nausea in 28% to 44% of patients, diarrhoea in 21% to 30% and constipation in 11% to 24%. Those are figures for a whole class rather than for semaglutide alone, and the counts inside the trials run higher. What the serious end of the record holds, which organs have been examined, who was excluded, and what the FDA enforcement record contains are set out on the safety page.

Question 14

Is semaglutide approved, and at what amounts?

Accepted Answer

Yes. Two uses, two amounts, and the two were granted at different times. A 2021 trial report refers to semaglutide 1·0 mg as the dose approved for diabetes treatment. A 2025 trial report states that once-weekly subcutaneous semaglutide 2·4 mg is approved for weight management in people with obesity and related complications. A 2023 JAMA review lists six medications currently approved by the US Food and Drug Administration for long-term use in obesity, and names semaglutide among them. That is a record of what a regulator decided, and it is not advice from us about what anybody should take. Approval is a fact about a made article, not about a molecule. It does not travel with the name into a compounded syringe or a research chemical listing.

Question 15

What does an approval actually cover?

Accepted Answer

No, and the difference is regulatory before it is chemical. Approval attaches to one injection or tablet, made by a named firm to a recipe filed with the regulator. A compounded or research-grade vial has no FDA-approved label, and nothing settled about the approved article has been settled about what is in it. The recall record shows what that looks like. FDA listings include a 10 mg per 4 mL multidose vial from a Pennsylvania compounder and a 5 mg/mL pre-filled syringe from a Colorado firm, both Class II recalls citing lack of assurance of sterility. One more covers a 2.5 mg/mL injection pulled as a subpotent drug. The approved supply appears there once as well. Wegovy pens were recalled in 2025 after a shipping error left them exposed to temperatures outside the labeled storage conditions. That is a failure of handling rather than a question about what was in the carton.

Question 16

Is semaglutide still being studied?

Accepted Answer

Yes, and well outside weight and diabetes. One trial registered as Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer’s Disease is recruiting. Another, registered to examine semaglutide’s effect on renal hemodynamics and function in patients with type 2 diabetes mellitus and nephropathy, carries an unknown status. Renal hemodynamics means blood flow through the kidney, and nephropathy means kidney disease. Two more have finished without a published result. A phase 3 study registered as the Latino Semaglutide Study is listed as completed, and so is a phase 2 study of a second compound added to semaglutide in participants with obesity. A registration is a plan rather than a result, and none of those four has reported. A plan tells a reader what someone hopes to find out, and nothing more than that.

Question 17

How does semaglutide work?

Accepted Answer

It copies a signal the body already uses, in several places at once. A 2021 review states that all GLP-1 receptor agonists share common mechanisms of action: augmentation of insulin secretion, suppression of glucagon secretion, deceleration of gastric emptying, and a reduction in calorie intake and body weight. Gastric emptying describes how quickly the stomach moves food onward into the gut. The receptor it acts on is not confined to the gut. A 2019 review records that the receptor is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. The receptors in the pancreas and brain have been shown to account for the respective improvements in glycemic control and body weight evident with liraglutide and semaglutide in people. One detail is easy to miss. Effects on gastric emptying decrease over time, a fading the authors call tachyphylaxis. Tachyphylaxis means the response to a repeated stimulus weakens, so one of the effects behind the early results fades.

Semaglutide